. Author manuscript; available in PMC: 2024 Jun 29.

Published in final edited form as: N Engl J Med. 2023 May 18;388(26):2434–2443. doi: 10.1056/NEJMoa2215201

Table 2.

Estimated Vaccine Effectiveness against Diagnosed Mpox among Persons Seeking Health Care, August 15 through November 19, 2022.^*

Persons Seeking Health Care	Case Patients	Control Patients	Vaccine Effectiveness (95% CI)
			Unadjusted	Adjusted^†
	number		percent
Unvaccinated, reference population	2022	6984
Partially vaccinated, 1 dose	146	1000	52.0 (42.3–60.1)	35.8 (22.1–47.1)
Fully vaccinated, 2 doses	25	335	77.2 (65.0–85.1)	66.0 (47.4–78.1)

CI denotes confidence interval.

^†

Adjustment was for age group (18 to 35, 36 to 49, and ≥50 years), race or ethnic group (non-Hispanic White, non-Hispanic Black, and other non-Hispanic), Social Vulnerability Index quartile (quartile 1 to 4, or unknown), and the presence or absence of an immunocompromising condition.